ErbB3 monoclonal antibody-drug conjugate (Sorrento Therapeutics)

N/A

Report date: 2025/03/20 20:00:06

Base Information

Drug NameErbB3 monoclonal antibody-drug conjugate (Sorrento Therapeutics)

Drug Alias NameN/A

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)Biologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Monoclonal antibody conjugate

Mechanisms of ActionReceptor tyrosine-protein kinase erbB-3 antagonists

TargetsReceptor tyrosine-protein kinase erbB-3

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesSorrento Therapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesSorrento Therapeutics Inc

Active IndicationsN/A

Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A